MTOR and breast cancer: Additionally, co-treatment of everolimus (RAD001) with the anti-estrogen drug exemestane (FCE-24304) for hormone receptor-positive breast cancer therapy showed alleviation of breast cancer by inactivating the mTOR signal in patients [111, 164, 165].